SCHEDULE: Genenta Science Shareholders Form Group, Challenge Corporate Actions

A group of Genenta Science shareholders has filed a Schedule 13D, announcing their formation and intent to monitor corporate actions and challenge recent amendments to the company's articles of association.

Summary

• A group of eleven individuals and entities, collectively referred to as the Reporting Persons, have filed a Schedule 13D statement indicating they may be considered a 'group' for regulatory purposes.
• These Reporting Persons collectively beneficially own approximately 23.0% of Genenta Science S.p.A.'s outstanding shares and 31.5% of the total voting power.
• The group has entered into a Shareholders' Agreement and Joint Filing Agreement dated May 4, 2026, to coordinate their actions and voting regarding Genenta Science.
• Their stated purpose is to promote the unity and stability of the company's strategic direction, monitor the legality of the board's actions, and specifically oppose the addition of new activities beyond the company's biotech focus.
• This opposition stems from a resolution adopted on October 29, 2025, which amended Article 4 of the company's Articles of Association to include a broad reference to 'Golden Power' sectors.
• The Reporting Persons deem this amendment null and void due to its vagueness.
• A subset of the Reporting Persons has already challenged this resolution, along with a previous resolution from May 2, 2024, introducing a selective multiple vote, in court.
• Proceedings are pending before the Court of Milan, including a request for an urgent precautionary measure to suspend the new corporate purpose.
• The group intends to consult on shareholder meeting matters and present a joint slate for the election of corporate bodies.
• The Reporting Persons have not acquired additional shares in connection with this filing and acquired their existing holdings using personal funds, totaling approximately $18.6 million.
• The agreement has a duration of five years.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the active legal challenges and opposition to corporate actions, indicating potential internal conflict and uncertainty.

Positives

• Formation of a significant shareholder group (23.0% of shares, 31.5% of voting power) aiming for strategic stability and oversight.
• Clear intent to monitor corporate governance and board actions.
• Agreement to coordinate voting and present joint slates for corporate body elections, potentially leading to more unified governance.
• Existing shareholdings were acquired using personal funds, indicating organic investment rather than speculative acquisition.
• The Shareholders' Agreement has a defined term of five years, suggesting a commitment to long-term engagement.

Negatives

• Active legal challenges against recent corporate resolutions (October 29, 2025, and May 2, 2024) regarding corporate purpose and voting mechanisms.
• The group considers the amendment to the Articles of Association regarding 'Golden Power' sectors to be vague and null and void.
• Pending legal proceedings in the Court of Milan, including a request for a precautionary measure to suspend the new corporate purpose, indicate significant internal discord.
• The formation of a 'group' and their stated intentions could lead to further shareholder activism and potential disruption.

Risks

• The ongoing legal proceedings and challenges to corporate resolutions could lead to uncertainty and potential delays in strategic execution.
• The group's opposition to the expansion of corporate activities beyond biotech could limit future growth opportunities if successful.
• Potential for continued shareholder activism and proxy battles if disagreements with the board are not resolved.
• The vagueness of the 'Golden Power' amendment, as perceived by the group, highlights potential governance issues.
• The five-year term of the agreement suggests a structured, long-term approach to activism, which could persist if objectives are not met.

Future Outlook

The Reporting Persons intend to promote the stability of Genenta's strategic direction within its biotech activities and oppose the addition of new activities under 'Golden Power' sectors. They will also monitor the legality of the board's actions and aim to present a joint slate for corporate body elections.

Industry Context

StockSavvy.ai notes that this filing reflects a common trend in the biotech sector where significant shareholders seek to influence corporate strategy and governance, particularly concerning the scope of business activities and board composition. The challenge to 'Golden Power' provisions is a notable aspect, indicating potential regulatory or strategic disagreements.

Corporate Governance

Legal Proceedings

• Proceedings pending before the Court of Milan, initiated on March 18, 2026, by Gaudenzio Roveda, BF & F S.r.l., Vyoda S.r.l., and Fin Posillipo S.p.A., challenging the extraordinary shareholders' meeting resolutions of October 29, 2025 (amendment to Article 4) and May 2, 2024 (selective multiple vote).
• These proceedings include a request for an urgent precautionary measure suspending the new corporate purpose.

Stakeholder Impact

• Shareholders: Potential for increased shareholder engagement and influence, but also risk of prolonged disputes and uncertainty.
• Board of Directors: Increased scrutiny of actions and potential challenges to strategic decisions.
• Company: Risk of operational disruption due to ongoing legal challenges and potential governance conflicts.

Next Steps

• The Reporting Persons will continue to monitor the legality of the Issuer's board of directors' actions.
• The Reporting Persons intend to consult with each other regarding any ordinary or extraordinary shareholders' meeting of the Issuer.
• The Reporting Persons intend to present a joint slate for the election of the members of the board of directors and the board of statutory auditors in view of shareholders' meetings convened for corporate body renewal.
• The legal proceedings before the Court of Milan will continue.

Key Dates

Recommendation

The formation of a significant shareholder group with a clear agenda and active legal challenges suggests potential for future activism and strategic shifts. However, the ongoing legal disputes and lack of financial performance data in this filing warrant a 'hold' position until the outcome of the legal proceedings and the company's strategic direction become clearer.

Keywords

Genenta Science, Schedule 13D, Shareholders Agreement, Joint Filing, Corporate Governance, Shareholder Activism, Board of Directors, Articles of Association, Golden Power, Court of Milan, Voting Rights, Ordinary Shares, American Depository Shares, Biotech